Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study

ConclusionPatients previously treated with benznidazole had significantly reduced parasitemia, a lower prevalence of markers of severe cardiomyopathy, and lower mortality after two years of follow-up. If used in the early phases, benznidazole treatment may improve clinical and parasitological outcomes in patients with chronic ChD. Trial, Trial registration: NCT02646943.
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research

Related Links:

This study investigates the therape utic efficacy of a vaccine prototype containing recombinant protein Tc24, formulated with an emulsion containing the Toll-like receptor 4 agonist E6020 as an immunomodulatory adjuvant in a mouse model of chronicT.cruzi infection. Among outbred ICR mice vaccinated during chronicT.cruzi infection, there is a significant increase in the number of animals with undetectable systemic parasitemia (60% of vaccinated mice compared to 0% in the sham vaccine control group), and a two-fold reduction in cardiac fibrosis over the control group. The vaccinated mice produce a robust protective TH1-biase...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
Abstract The infection with the protozoan parasite Trypanosoma cruzi causes Chagas disease, a neglected tropical disease in Latin America and an imported emerging disease worldwide. Chronic Chagasic cardiomyopathy (CCC), a progressive inflammatory and fibrosing disease, is the most prominent clinical form of Chagas disease, culminating in heart failure and high rates of sudden death. CCC pathogenesis is influenced by both host and parasite factors and is proposed to be mostly immune-driven. Chemokines are crucial players in orchestrating immune cell recruitment to infected tissues and inflammation. Herein, we...
Source: Journal of Leukocyte Biology - Category: Hematology Authors: Tags: J Leukoc Biol Source Type: research
This study was performed in accordance with the ethical standards of the Institutional Animal Care and Use Committee (IACUC, approval FUA-007-14) from the Unidad de Biología Comparativa (UBA) at Pontificia Universidad Javeriana (PUJ, Bogotá, Colombia). All animal studies were conducted in accordance with the “Guide for the Care and Use of Laboratory Animals” from UBA-PUJ. The present study was described according to the Animal Research: Reporting in vivo Experiments (ARRIVE) criteria from the National Center for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (32). Mice ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: We suggest some distinct molecular mechanisms for production of IL-1β in innate immune cells from patients with different clinical forms of Chagas disease. MMP-2 and MMP-9 gelatinases are associated with distinct disease outcomes and IL-1β production. Introduction Chagas disease, also known as American trypanosomiasis, is a neglected parasitic disease caused by the protozoan Trypanosoma cruzi (1), that affects millions of people in the world (2). During the acute phase, a diffuse and intense inflammation in the cardiomyocytes is observed, which is composed mainly of neutrophils, monocytes, and ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
American trypanosomiasis is caused by a parasite endemic of the Americas. Current migration has globalized Chagas disease. Acute infection usually resolves spontaneously. Nonetheless, 20% to 40% develop cardiomyopathy 20 to 30  years later. Progression to cardiomyopathy is devastatingly rapid, manifesting with heart failure and sudden death. Etiologic treatment is highly effective and recommended in those with acute infections, congenital infections, and parasite reactivation, and women of childbearing age, but in asympt omatic Trypanosoma cruzi carriers and patients with early cardiomyopathy remains controversial and...
Source: Infectious Diseases Clinics of North America - Category: Infectious Diseases Authors: Source Type: research
Conclusions/SignificanceThe different clinical stages of chronic Chagas disease display distinct monocyte profiles that are restored after anti-parasite drug therapy.T.cruzi-infected subjects with severe cardiac disease displayed a profile of monocytes subsets suggestive of a more pronounced inflammatory environment compared with subjects suffering from heart failure not related toT.cruzi infection, supporting that parasite persistence might also alter cell components of the innate immune system.
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
AbstractPurpose of ReviewChagas disease (CD) is endemic to much of Latin America, but also present in the United States (U.S.). Following a lengthy asymptomatic period, CD produces serious cardiac or gastrointestinal complications in 30 –40% of people. Less than 1% of the estimated six million cases in the Americas, including 326,000–347,000 in the U.S., are diagnosed. Infected persons are typically unaware and the bulk of clinicians are unfamiliar with current treatment guidelines. This review provides U.S. and other clinician s with the latest knowledge of CD treatment.Recent FindingsChagas cardiomyopathy (CC...
Source: Current Treatment Options in Infectious Diseases - Category: Infectious Diseases Source Type: research
Conclusions/SignificanceThe positive outcomes achieved in the absence of sterile cure suggest that the target product profile in anti-Chagasic drug discovery should be revised in favor of safe re-administration of the medication during the lifespan of a Chagas disease patient. A medication that reduces parasite burden may halt or slow progression of cardiomyopathy and therefore improve both life expectancy and quality of life.
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
We report two examples of Chagas cardiomyopathy in South American women permanently residing in Italy for more than 20 years, presenting with cardiac manifestations ranging from left ventricular dysfunction and heart failure to isolated ventricular arrhythmias. The present review emphasizes that Chagas disease should be considered as a potential diagnosis in patients from endemic areas presenting with ‘idiopathic’ cardiac manifestations, even when long removed from their country of origin, with potential implications for treatment and control of Chagas disease transmission.
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Arrhythmias Source Type: research
Conclusions. These results suggest that galectin-3 is strongly involved in Chagas disease, not only in the immune response against T. cruzi, but also in mediating cardiac tissue damage.
Source: The Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: PATHOGENESIS AND HOST RESPONSE Source Type: research
More News: Brazil Health | Cardiology | Cardiomyopathy | Chagas Disease | Electrocardiogram | Heart | Heart Failure | Legislation | Parasitic Diseases | Parasitology | Study